BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33536751)

  • 41. Single inhaler triple therapy for COPD.
    Drug Ther Bull; 2017 Dec; 55(12):138-141. PubMed ID: 29237699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.
    Ming SWY; Haughney J; Ryan D; Small I; Lavorini F; Papi A; Singh D; Halpin DMG; Hurst JR; Patel S; Ochel M; Kocks J; Carter V; Hardjojo A; Price DB
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3093-3103. PubMed ID: 33273812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
    Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
    NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Trimbow® : twice-daily triple combination for the treatment of COPD].
    Corhay JL; Bonhomme O; Guiot J
    Rev Med Liege; 2018 Sep; 73(9):480-484. PubMed ID: 30188035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study".
    Porpodis K; Bartziokas K; Chatziapostolou P; Korkontzelou A; Katerelos P; Efstathopoulos P; Bakakos P
    Respir Med; 2023 Jun; 212():107219. PubMed ID: 36965590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
    Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
    J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
    N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S; Criner GJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study.
    Gessner C; Trinkmann F; Bahari Javan S; Hövelmann R; Bogoevska V; Georges G; Nudo E; Criée CP
    Int J Chron Obstruct Pulmon Dis; 2022; 17():3019-3031. PubMed ID: 36483674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
    Singh D; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
    Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease.
    Pudi K; Feldman G; Fakih F; Mack P; Maes A; Siddiqui S; St Rose E; Reisner C
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):40-46. PubMed ID: 30335559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.